株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

特発性肺線維症:パイプライン製品の分析

Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2018

発行 Global Markets Direct 商品コード 232804
出版日 ページ情報 英文 302 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.57円で換算しております。
Back to Top
特発性肺線維症:パイプライン製品の分析 Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2018
出版日: 2018年04月30日 ページ情報: 英文 302 Pages
概要

特発性肺線維症(IPF)は、肺の孤立性の進行性疾患です。空咳、息切れ(特に運動中/運動後)、持続的な疲労、体重減少などの症状が見られます。治療は、抗酸化剤、生物学的反応修飾物質、抗線維化剤、抗凝固剤などが含まれます。

当レポートでは、特発性肺線維症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

I特発性肺線維症 - 概要

I特発性肺線維症 - 治療薬の開発

  • パイプラインの概要
  • 企業別のパイプライン動向
  • 大学・研究機関別のパイプライン動向
  • 企業で開発中の製品
  • 大学・研究機関で開発中の製品

I特発性肺線維症 - 治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

I特発性肺線維症の治療薬開発に従事している企業

  • AdAlta Ltd
  • Aeolus Pharmaceuticals Inc
  • Allinky Biopharma
  • apceth Biopharma GmbH
  • Apellis Pharmaceuticals Inc
  • 旭化成ファーマ
  • aTyr Pharma Inc
  • Biogen Inc
  • Bioneer Corp
  • BLR Bio LLC
  • Bristol-Myers Squibb Company
  • Celgene Corp
  • Celldex Therapeutics Inc
  • Chiesi Farmaceutici SpA
  • Compugen Ltd
  • Cynata Therapeutics Ltd
  • F. Hoffmann-La Roche Ltd
  • FibroGen Inc
  • FibroStatin SL
  • Galapagos NV
  • GenKyoTex SA
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd
  • Global Blood Therapeutics Inc
  • GNI Group Ltd
  • Histocell SL
  • iBio Inc
  • Inventiva
  • Isarna Therapeutics GmbH
  • Kadmon Corp LLC
  • Kasiak Research Pvt Ltd
  • Kyorin Pharmaceutical Co Ltd
  • Lung Therapeutics Inc
  • Merck & Co Inc
  • miRagen Therapeutics Inc
  • MorphoSys AG
  • Nuevolution AB
  • Pharmaxis Ltd
  • Promedior Inc
  • ProMetic Life Sciences Inc
  • Pulmatrix Inc
  • Re-Pharm Ltd
  • Redx Pharma Plc
  • Respira Therapeutics Inc
  • Ribomic Inc
  • Saje Pharma LLC
  • Samumed LLC
  • Sanofi
  • Sorrento Therapeutics Inc
  • SPR Biosciences LLC
  • Therabron Therapeutics Inc
  • Unity Biotechnology Inc
  • Vicore Pharma AB
  • Yuhan Corp

薬剤プロファイル

I特発性肺線維症 - 休止中のプロジェクト

I特発性肺線維症 - 開発が中止された製品

I特発性肺線維症 - 製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

目次
Product Code: GMDHC10372IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2018, provides an overview of the Idiopathic Pulmonary Fibrosis (Respiratory) pipeline landscape.

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease characterized by inflammation and scarring of lung tissue and loss of lung function. Symptoms of IPF include dry cough, shortness of breath, especially during or after physical activity, lasting tiredness and weight loss. Risk factors include smoking, environmental exposure, viral infections, family history and abnormal acid reflux. Treatment includes antioxidants, biological response modulators, anti-fibrotic agents and anticoagulants.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Idiopathic Pulmonary Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 15, 17, 1, 67 and 12 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 3 molecules, respectively.

Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Idiopathic Pulmonary Fibrosis (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Idiopathic Pulmonary Fibrosis - Overview
  • Idiopathic Pulmonary Fibrosis - Therapeutics Development
  • Idiopathic Pulmonary Fibrosis - Therapeutics Assessment
  • Idiopathic Pulmonary Fibrosis - Companies Involved in Therapeutics Development
  • Idiopathic Pulmonary Fibrosis - Drug Profiles
  • Idiopathic Pulmonary Fibrosis - Dormant Projects
  • Idiopathic Pulmonary Fibrosis - Discontinued Products
  • Idiopathic Pulmonary Fibrosis - Product Development Milestones
  • Appendix

List of Tables

  • Table 1: Number of Products under Development for Idiopathic Pulmonary Fibrosis, H1 2018
  • Table 2: Number of Products under Development by Companies, H1 2018
  • Table 3: Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Table 4: Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018
  • Table 5: Number of Products under Development by Companies, H1 2018 (Contd..3), H1 2018
  • Table 6: Number of Products under Development by Companies, H1 2018 (Contd..4), H1 2018
  • Table 7: Number of Products under Development by Universities/Institutes, H1 2018
  • Table 8: Products under Development by Companies, H1 2018
  • Table 9: Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Table 10: Products under Development by Companies, H1 2018 (Contd..2), H1 2018
  • Table 11: Products under Development by Companies, H1 2018 (Contd..3), H1 2018
  • Table 12: Products under Development by Companies, H1 2018 (Contd..4), H1 2018
  • Table 13: Products under Development by Companies, H1 2018 (Contd..5), H1 2018
  • Table 14: Products under Development by Universities/Institutes, H1 2018
  • Table 15: Number of Products by Stage and Target, H1 2018
  • Table 16: Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018
  • Table 17: Number of Products by Stage and Target, H1 2018 (Contd..2), H1 2018
  • Table 18: Number of Products by Stage and Target, H1 2018 (Contd..3), H1 2018
  • Table 19: Number of Products by Stage and Mechanism of Action, H1 2018
  • Table 20: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018
  • Table 21: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..2), H1 2018
  • Table 22: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..3), H1 2018
  • Table 23: Number of Products by Stage and Route of Administration, H1 2018
  • Table 24: Number of Products by Stage and Molecule Type, H1 2018
  • Table 25: Idiopathic Pulmonary Fibrosis - Pipeline by Abeome Corp, H1 2018
  • Table 26: Idiopathic Pulmonary Fibrosis - Pipeline by AdAlta Ltd, H1 2018
  • Table 27: Idiopathic Pulmonary Fibrosis - Pipeline by Aeolus Pharmaceuticals Inc, H1 2018
  • Table 28: Idiopathic Pulmonary Fibrosis - Pipeline by Allinky Biopharma, H1 2018
  • Table 29: Idiopathic Pulmonary Fibrosis - Pipeline by AnaMar AB, H1 2018
  • Table 30: Idiopathic Pulmonary Fibrosis - Pipeline by apceth Biopharma GmbH, H1 2018
  • Table 31: Idiopathic Pulmonary Fibrosis - Pipeline by Asahi Kasei Corp, H1 2018
  • Table 32: Idiopathic Pulmonary Fibrosis - Pipeline by BerGenBio ASA, H1 2018
  • Table 33: Idiopathic Pulmonary Fibrosis - Pipeline by Biogen Inc, H1 2018
  • Table 34: Idiopathic Pulmonary Fibrosis - Pipeline by Bioneer Corp, H1 2018
  • Table 35: Idiopathic Pulmonary Fibrosis - Pipeline by Boehringer Ingelheim GmbH, H1 2018
  • Table 36: Idiopathic Pulmonary Fibrosis - Pipeline by BreStem Therapeutics Inc, H1 2018
  • Table 37: Idiopathic Pulmonary Fibrosis - Pipeline by Bristol-Myers Squibb Co, H1 2018
  • Table 38: Idiopathic Pulmonary Fibrosis - Pipeline by Celgene Corp, H1 2018
  • Table 39: Idiopathic Pulmonary Fibrosis - Pipeline by Chiesi Farmaceutici SpA, H1 2018
  • Table 40: Idiopathic Pulmonary Fibrosis - Pipeline by Compugen Ltd, H1 2018
  • Table 41: Idiopathic Pulmonary Fibrosis - Pipeline by Cynata Therapeutics Ltd, H1 2018
  • Table 42: Idiopathic Pulmonary Fibrosis - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
  • Table 43: Idiopathic Pulmonary Fibrosis - Pipeline by FibroGen Inc, H1 2018
  • Table 44: Idiopathic Pulmonary Fibrosis - Pipeline by FibroStatin SL, H1 2018
  • Table 45: Idiopathic Pulmonary Fibrosis - Pipeline by Galapagos NV, H1 2018
  • Table 46: Idiopathic Pulmonary Fibrosis - Pipeline by Galecto Biotech AB, H1 2018
  • Table 47: Idiopathic Pulmonary Fibrosis - Pipeline by GenKyoTex SA, H1 2018
  • Table 48: Idiopathic Pulmonary Fibrosis - Pipeline by GlaxoSmithKline Plc, H1 2018
  • Table 49: Idiopathic Pulmonary Fibrosis - Pipeline by Glenmark Pharmaceuticals Ltd, H1 2018
  • Table 50: Idiopathic Pulmonary Fibrosis - Pipeline by Global Blood Therapeutics Inc, H1 2018
  • Table 51: Idiopathic Pulmonary Fibrosis - Pipeline by iBio Inc, H1 2018
  • Table 52: Idiopathic Pulmonary Fibrosis - Pipeline by Inventiva, H1 2018
  • Table 53: Idiopathic Pulmonary Fibrosis - Pipeline by Isarna Therapeutics GmbH, H1 2018
  • Table 54: Idiopathic Pulmonary Fibrosis - Pipeline by Kadmon Corp LLC, H1 2018
  • Table 55: Idiopathic Pulmonary Fibrosis - Pipeline by Kasiak Research Pvt Ltd, H1 2018
  • Table 56: Idiopathic Pulmonary Fibrosis - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2018
  • Table 57: Idiopathic Pulmonary Fibrosis - Pipeline by Lung Therapeutics Inc, H1 2018
  • Table 58: Idiopathic Pulmonary Fibrosis - Pipeline by Medicenna Therapeutics Corp, H1 2018
  • Table 59: Idiopathic Pulmonary Fibrosis - Pipeline by Merck & Co Inc, H1 2018
  • Table 60: Idiopathic Pulmonary Fibrosis - Pipeline by Miragen Therapeutics Inc, H1 2018
  • Table 61: Idiopathic Pulmonary Fibrosis - Pipeline by Mission Therapeutics Ltd, H1 2018
  • Table 62: Idiopathic Pulmonary Fibrosis - Pipeline by Moerae Matrix Inc, H1 2018
  • Table 63: Idiopathic Pulmonary Fibrosis - Pipeline by Novartis AG, H1 2018
  • Table 64: Idiopathic Pulmonary Fibrosis - Pipeline by Nuevolution AB, H1 2018
  • Table 65: Idiopathic Pulmonary Fibrosis - Pipeline by Nuformix Plc, H1 2018
  • Table 66: Idiopathic Pulmonary Fibrosis - Pipeline by OliX Pharmaceuticals Inc, H1 2018
  • Table 67: Idiopathic Pulmonary Fibrosis - Pipeline by Pharmaxis Ltd, H1 2018
  • Table 68: Idiopathic Pulmonary Fibrosis - Pipeline by Promedior Inc, H1 2018
  • Table 69: Idiopathic Pulmonary Fibrosis - Pipeline by ProMetic Life Sciences Inc, H1 2018
  • Table 70: Idiopathic Pulmonary Fibrosis - Pipeline by Pulmatrix Inc, H1 2018
  • Table 71: Idiopathic Pulmonary Fibrosis - Pipeline by Re-Pharm Ltd, H1 2018
  • Table 72: Idiopathic Pulmonary Fibrosis - Pipeline by Redx Pharma Plc, H1 2018
  • Table 73: Idiopathic Pulmonary Fibrosis - Pipeline by Respira Therapeutics Inc, H1 2018
  • Table 74: Idiopathic Pulmonary Fibrosis - Pipeline by Reviva Pharmaceuticals Inc, H1 2018
  • Table 75: Idiopathic Pulmonary Fibrosis - Pipeline by Ribomic Inc, H1 2018
  • Table 76: Idiopathic Pulmonary Fibrosis - Pipeline by Saje Pharma LLC, H1 2018
  • Table 77: Idiopathic Pulmonary Fibrosis - Pipeline by Samumed LLC, H1 2018
  • Table 78: Idiopathic Pulmonary Fibrosis - Pipeline by Shionogi & Co Ltd, H1 2018
  • Table 79: Idiopathic Pulmonary Fibrosis - Pipeline by Sorrento Therapeutics Inc, H1 2018
  • Table 80: Idiopathic Pulmonary Fibrosis - Pipeline by Taiho Pharmaceutical Co Ltd, H1 2018
  • Table 81: Idiopathic Pulmonary Fibrosis - Pipeline by Telocyte LLC, H1 2018
  • Table 82: Idiopathic Pulmonary Fibrosis - Pipeline by Therabron Therapeutics Inc, H1 2018
  • Table 83: Idiopathic Pulmonary Fibrosis - Pipeline by Unity Biotechnology Inc, H1 2018
  • Table 84: Idiopathic Pulmonary Fibrosis - Pipeline by Vicore Pharma AB, H1 2018
  • Table 85: Idiopathic Pulmonary Fibrosis - Pipeline by X-Rx Inc, H1 2018
  • Table 86: Idiopathic Pulmonary Fibrosis - Pipeline by Yuhan Corp, H1 2018
  • Table 87: Idiopathic Pulmonary Fibrosis - Pipeline by Zai Lab Ltd, H1 2018
  • Table 88: Idiopathic Pulmonary Fibrosis - Dormant Projects, H1 2018
  • Table 89: Idiopathic Pulmonary Fibrosis - Dormant Projects, H1 2018 (Contd..1), H1 2018
  • Table 90: Idiopathic Pulmonary Fibrosis - Dormant Projects, H1 2018 (Contd..2), H1 2018
  • Table 91: Idiopathic Pulmonary Fibrosis - Dormant Projects, H1 2018 (Contd..3), H1 2018
  • Table 92: Idiopathic Pulmonary Fibrosis - Discontinued Products, H1 2018

List of Figures

  • Figure 1: Number of Products under Development for Idiopathic Pulmonary Fibrosis, H1 2018
  • Figure 2: Number of Products under Development by Companies, H1 2018
  • Figure 3: Number of Products under Development by Universities/Institutes, H1 2018
  • Figure 4: Number of Products by Top 10 Targets, H1 2018
  • Figure 5: Number of Products by Stage and Top 10 Targets, H1 2018
  • Figure 6: Number of Products by Top 10 Mechanism of Actions, H1 2018
  • Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
  • Figure 8: Number of Products by Routes of Administration, H1 2018
  • Figure 9: Number of Products by Stage and Routes of Administration, H1 2018
  • Figure 10: Number of Products by Top 10 Molecule Types, H1 2018
  • Figure 11: Number of Products by Stage and Top 10 Molecule Types, H1 2018
Back to Top